NAD+ and Sermorelin Together: What Is Known
NAD+ and Sermorelin taken together: what each one is, how each is regulated, and what is known about combining them.
Timing, interactions and safety
Evidence for the combination
No studies tested these together (PubMed search: 0 results, 2 Oct 2026).
Side by side
Showing 9 of 10 fields where the two differ. PCAC vote, Jul 2026 are the same or both unknown.
| Field | NAD+ | Sermorelin |
|---|---|---|
| Class | Coenzyme (injectable, IV or nasal) | GHRH analog |
| Also called | NAD, nicotinamide adenine dinucleotide | — |
| FDA status | Compounded | Compounded by prescription |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | No WADA record in our data | Prohibited by WADA (S2.2.4)Sermorelin is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times. |
| Anti-doping detection | None reportedanti-doping literature, as of 2 Oct 2026 |
|
| Half-life | [half-life by route] | No published half-life foundPubMed search, 11 Oct 2026 |
| Evidence strength | [evidence grade] | Human RCT evidence, 4 of 4Strongest: The Journal of clinical endocrinology and metabolism 1992, PMID 1379256 |
| Human studies we summarised | [n] | 6 human (1 randomized or controlled) of 9 summarised |
| Typical study doses | [dose range] |
|
NAD+ vs Sermorelin
Choosing between the two rather than combining them? The comparison lines them up field by field.
NAD+: what the reviews say
A systematic review of NAD+ studies reports that rodent results were often positive, while human oral precursors mainly showed biochemical target engagement.[11]
A retrospective look at commercial infusions of NAD+ states that safety and effectiveness have had limited evaluation.[14]
Sermorelin
Sermorelin is a 29 amino acid GHRH analogue that stimulates GH secretion from the pituitary.[15]
Geref, the US recombinant GHRH product, was discontinued by its manufacturer in 2008.[16]
Sermorelin tolerability
In the paediatric trial of the sermorelin sequence, no adverse changes in general biochemical or hormonal analyses were noted.[12]
Together
The dataset search for NAD+ with sermorelin returned 0 PubMed records.
Calculated from pubmed query ("NAD+"[tiab] OR "nicotinamide adenine dinucleotide"[tiab]) AND (sermorelin[tiab] OR Geref[tiab]); search date 2026-10-02; records returned 0; records classed as study of the pair 0. Formula: Counts copied from the combinations dataset (web/src/data/combinations.json, key nad__sermorelin); no arithmetic applied.
A review defines NAD+ as a cofactor for NAD+-dependent enzymes that regulate DNA repair, cellular metabolism and immune function.[14]
Common questions
Can you take NAD+ with sermorelin?
There is no study of the pair; the NAD+ review found no eligible outcomes trials of intravenous or intramuscular NAD+ itself for anti-aging or wellness.[11]
NAD vs sermorelin: which does what?
Sermorelin stimulates GH secretion from the anterior pituitary, while NAD+ is a cofactor for enzymes in DNA repair, metabolism and immune function.[15]
Sources
- 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 2An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
- 3Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
- 4Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.The Journal of clinical endocrinology and metabolism · 1992PMID 1379256Accessed 2 Oct 2026
- 5Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels.American journal of men's health · 2017PMID 28830317Accessed 2 Oct 2026
- 6Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.Metabolism: clinical and experimental · 1997PMID 9005976Accessed 2 Oct 2026
- 7PubMed search: (sermorelin[tiab] OR Geref[tiab]) (34 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 8PubMed search: (sermorelin[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab] OR "GHRH 1-29"[tiab]) AND (elderly[tiab] OR aging[tiab] OR "older adults"[tiab] OR adults[tiab]) AND (treatment[tiab] OR therapy[tiab] OR administration[tiab]) (15 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9PubMed search: (sermorelin[tiab] OR Geref[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10PubMed search: ("NAD+"[tiab] OR "nicotinamide adenine dinucleotide"[tiab]) AND (sermorelin[tiab] OR Geref[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 11NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence.Ageing research reviews · 2026PMID 41655607Accessed 2 Oct 2026
- 12Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group.The Journal of clinical endocrinology and metabolism · 1996PMID 8772599Accessed 2 Oct 2026
- 13PubMed search: (sermorelin[tiab] OR Geref[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (21 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 14Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting.Frontiers in aging · 2026PMID 41704678Accessed 2 Oct 2026
- 15Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 1999PMID 18031173Accessed 2 Oct 2026
- 16Clinical review: Is lack of recombinant growth hormone (GH)-releasing hormone in the United States a setback or time to consider glucagon testing for adult GH deficiency?The Journal of clinical endocrinology and metabolism · 2009PMID 19509104Accessed 2 Oct 2026
Found an error? Report a correction.